CONVERTIBLE NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2014

Notes to Financial Statements

Schedule of Conversions of Stock

Convertible Notes Payable at consists of the following:	March 31,			December 31,
	2014			2013
$52,476 face value,10% unsecured note payable to an investor, note interest and payment are due on demand.  The note could be converted to option rights for Skinvisible, Inc. shares at ten cents per share ($0.10), these rights expired January 12, 2010. Note is currently in default, no penalties occur due to default.	$	36,476		$	36,476
$27,000 face value 10% unsecured notes payable to investors, due October, 2012.  At the written request of the investor’s until the repayment date, the note may be converted at the investors option to shares of the Company’s common stock at a fixed price of $0.05 per share along with additional warrants to purchase one share for every two shares issued at the exercise price of $0.07 per share for two years after the conversion date. The Company has determined the value associated with the beneficial conversion feature in connection with the notes to be $19,385. The aggregate beneficial conversion feature was accreted and charged to general and administrative expenses as a financing expense in the amount of $19,385 in the year ending December 31, 2012.  The beneficial conversion feature is valued under the intrinsic value method.  Interest due to lender can also be converted at a rate of ($0.05) per share into warrants.		5,000			10,000
$1,000,000 face value 9% unsecured notes payable to investors, due in 2015.  At the investor’s option until the repayment date, the note and related interest may be converted to shares of the Company’s common stock a discount of  90% of the current share price after the first anniversary of the note. The Notes are secured by the accounts receivable of a license agreement the Company has with Womens Choice Pharmaceuticals, LLC on its proprietary prescription product, ProCort®. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $111,110. The aggregate original issue discount feature has been accreted and charged to general and administrative expenses as a financing expense in the amount of $12,144 during the three months ended March 31, 2014.  The original issue discount feature is valued under the intrinsic value method.		1,000,000			1,000,000
Original issue discount		111,110			111,110
Unamortized debt discount		(54,345	)		(66,490	)
	$	1,098,241		$	1,091,097